Lyon (France), March 11, 2015 - Valneva SE ("Valneva"), a leading pure play vaccines biotech company, announced today that it has signed a new research license agreement with Merial and a commercial ...

The Company which has already signed seven new EB66® deals since the beginning of the year expects to sign additional EB66® agreements in the second half of 2015 Valneva further anticipates that ...

Lyon (France), March 24, 2014 - European biotechnology company Valneva SE (Valneva) announced today that the Chemo-Sero Therapeutic Research Institute (Kaketsuken), a co-development partner to ...

Novavax and Vivalis announced the completion of a research license to use the Vivalis proprietary EB66 cell line, for the production of Novavax VLP based vaccines. Through this collaboration, Novavax ...

Valneva has already made 5 deals this year for vaccine makers to use its EB66 cell line, which is derived from duck embryonic stem cells, allowing for faster vaccine manufacturing. Now, it is adding ...

Potentially €4 million agreement will lead to production of clinical trials material for GeoVax at Vivalis’ facility. GeoVax and Vivalis signed a potentially €4 million biomanufacturing agreement for ...

Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines ROCKVILLE, Md. and NANTES ...

Valneva SE has announced that it has signed an exclusive license agreement with the Chinese company Jianshun Biosciences Ltd to commercialize Valneva’s EB66® cell line for the manufacturing of human ...

PARIS, Nov 24 (Reuters) - French biotech Vivalis and its British partner GlaxoSmithKline have won U.S. clearance to begin testing for the first time on humans flu vaccines that were produced using ...

Transgene is looking for alternative platform to manufacture clinical-stage cancer and infectious disease vaccines. Transgene and Vivalis signed a commercial license and collaboration agreement to ...

* BioDiem confirms successful and abundant growth of its virus in VIVALIS' proprietary EB66(®) cell line in Stage 1 of its collaboration with VIVALIS. * The next stage of the project will use known ...

* New EB66 commercial license with an undisclosed European veterinary company * Announces that it has signed a new research license agreement with Merial and a commercial license agreement with an ...